Please login to the form below

Not currently logged in
Email:
Password:

Millennium expands Velcade tests

Millennium Pharmaceuticals begins tests to evaluate its blood cancer drug Velcade in combination with other drugs

Millennium Pharmaceuticals has begun tests to evaluate its blood cancer drug Velcade (bortezomib) in combination with other drugs.

Velcade, which Millennium is developing with Johnson & Johnson Pharmaceutical Research and Development (J&JPRD), can be prescribed to patients with multiple myeloma who have received at least one prior therapy.

The phase II trial will evaluate the efficacy of combining Velcade for injection with lenalidomide, dexamethasone and cyclophosphamide in the front-line multiple myeloma setting.

In a press statement, Millennium's CMO Nancy Simonian, said: "The objective of this trial is to evolve the treatment of multiple myeloma by combining these highly active therapies to induce early complete remission and improve long term survival."

16th August 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...
A snapshot of… Exscientia
...

Infographics